Evidence map›Paper›PMID 36798291›Full record

ArticlebioRxiv : the preprint server for biology2023

Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.

Marta Sanz, Ann Marie K Weideman, Adam R Ward, Matthew L Clohosey, Susana Garcia-Recio, Sara R Selitsky, Brendan T Mann, Marie Anne Iannone, Chloe P Whitworth, Alisha Chitrakar and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Marta SanzDepartment of Microbiology Immunology and Tropical Medicine, the George Washington University, Washington DC, USA.
Ann Marie K WeidemanDepartment of Biostatistics, University of North Carolina at Chapel Hill, North Carolina, USA.
Adam R WardDepartment of Microbiology Immunology and Tropical Medicine, the George Washington University, Washington DC, USA.
Matthew L ClohoseyUNC HIV-1 Cure Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Susana Garcia-RecioLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Sara R SelitskyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Brendan T MannDepartment of Microbiology Immunology and Tropical Medicine, the George Washington University, Washington DC, USA.
Marie Anne IannoneLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Chloe P WhitworthUNC HIV-1 Cure Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Alisha ChitrakarDepartment of Microbiology Immunology and Tropical Medicine, the George Washington University, Washington DC, USA.
Carolina GarridoUNC HIV-1 Cure Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Jennifer KirchherrUNC HIV-1 Cure Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Alisha R CoffeyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Yi-Hsuan TsaiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Shahryar SamirMicrobiology & Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Yinyan XuMicrobiology & Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Dennis CopertinoDepartment of Infectious Diseases, Weill Cornell Medicine, New York, USA.
Alberto BosqueDepartment of Microbiology Immunology and Tropical Medicine, the George Washington University, Washington DC, USA.
Brad R JonesDepartment of Microbiology Immunology and Tropical Medicine, the George Washington University, Washington DC, USA.
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Michael G HudgensDepartment of Biostatistics, University of North Carolina at Chapel Hill, North Carolina, USA.
Nilu GoonetillekeMicrobiology & Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Natalia Soriano-SarabiaDepartment of Microbiology Immunology and Tropical Medicine, the George Washington University, Washington DC, USA.
University of North Carolina at Chapel Hill · USGeorge Washington University · USCornell University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
Biostatistics for Research in Genomics and CancerT32CA106209 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOSEPH G IBRAHIM, Naim Ur Rashid · 2004 to 2026
$4.8M
Peripheral and tissue-resident gamm/delta T cells in HIV latencyR01AI125097 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SORIANO-SARABIA, NATALIA · 2016 to 2020
$2.7M
Allogeneic cytotoxic gammadelta T cells for HIV cure immunotherapyR21AI157864 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI SORIANO-SARABIA, NATALIA · 2021 to 2022
$436k
NCI NIH HHS P30 CA016086NCI NIH HHS T32 CA106209NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI125097NIAID NIH HHS R21 AI157864NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

Antiretroviral therapy (ART) is not curative due to the existence of cellular reservoirs of latent HIV-1 that persist during therapy. Current research efforts to cure HIV-1 infection include "shock and kill" strategies to disrupt latency using small molecules or latency-reversing agents (LRAs) to induce expression of HIV-1 enabling cytotoxic immune cells to eliminate infected cells. The modest success of current LRAs urges the field to identify novel drugs with increased clinical efficacy. Aminobisphosphonates (N-BPs) that include pamidronate, zoledronate, or alendronate, are the first-line treatment of bone-related diseases including osteoporosis and bone malignancies. Here, we show the use of N-BPs as a novel class of LRA: we found in

Identifiers

PMID36798291
PMCPMC9934553
OpenAlexW4319341255

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.